Nihal Karaçayır

Dr. Nihal Karaçayır

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
EYEmine Nur Sunar Yayla
Emine Nur Sunar Yayla
ÇYÇisem Yıldız
Çisem Yıldız
PŞPelin Şenol
Pelin Şenol
NKNihal Karaçayır
Nihal Karaçayır
DYDeniz Gezgin Yıldırım
Deniz Gezgin Yıldırım
SESEVCAN AZIME BAKKALOGLU EZGU
SEVCAN AZIME BAKKALOGLU EZGU
Adverse events,biological treatments,pediatric rheumatology

1 April 2008 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
ZBZelal Bircan
Zelal Bircan
NKNihal Karaçayır
Nihal Karaçayır
HCHae Il Cheong
Hae Il Cheong

23 September 2022 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
DYDeniz Gezgin Yıldırım
Deniz Gezgin Yıldırım
ÇYÇisem Yıldız Yıldırım
Çisem Yıldız Yıldırım
NKNihal Karaçayır
Nihal Karaçayır
PŞPelin Şenol
Pelin Şenol
EYEmine Nur Sunar Yayla
Emine Nur Sunar Yayla
SESEVCAN AZIME BAKKALOGLU EZGU
SEVCAN AZIME BAKKALOGLU EZGU

8 January 2024 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
NKNihal Karaçayır
Nihal Karaçayır
ŞTŞerife Tunçez
Şerife Tunçez
NÖNimet Öner
Nimet Öner
EÇElif Çelikel
Elif Çelikel
EBEsra Bağlan
Esra Bağlan
SBSevcan A. Bakkaloğlu
Sevcan A. Bakkaloğlu
Objective: Chronic nonbacterial osteomyelitis (CNO) is a noninfectious autoinflammatory bone condition that frequently occurs alongside other inflammatory diseases, such as familial Mediterranean fever (FMF). We aimed to determine the demographic, clinical, laboratory, and radiological characteristics of patients diagnosed with both FMF and CNO. Methods: We reviewed the medical records of pediatric patients with both CNO and FMF at 3 pediatric rheumatology centers in Turkey from December 2008 to 2022. Patients' demographics, laboratory features, imaging findings, and treatment were recorded. Results: Twelve patients with FMF and CNO were included in the study. Half of them were girls. The mean ages at onset for FMF and CNO symptoms were 80 and 116 months, whereas the ages at diagnosis for FMF and CNO were 100 and 125 months, respectively. Ten patients (83.3%) had M694V mutation on at least 1 allele of the Mediterranean fever (MEFV) gene. The most common sites of osteitis were the long bones (58.3%), pelvis (50%), and clavicles (25%). Ten patients (83%) received nonsteroidal anti-inflammatory drugs; 8 (66%) received disease-modifying antirheumatic drugs; biological therapy was administered to 5 patients (41%), who did not respond to these treatments; and all patients received colchicine. Conclusion: The increased frequency of FMF in patients with CNO is of interest. Because most patients with CNO and FMF carried a homozygous or combined heterozygous M694V mutation, we speculated that the M694V mutation may play a role in the development of osteitis. Further studies are needed to elucidate the link between FMF and CNO.

19 March 2025 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
ÇYÇisem Yıldız
Çisem Yıldız
BKBatuhan Küçükali
Batuhan Küçükali
MKMerve Kutlar
Merve Kutlar
NBNuran Belder
Nuran Belder
NKNihal Karaçayır
Nihal Karaçayır
SESEVCAN AZIME BAKKALOGLU EZGU
SEVCAN AZIME BAKKALOGLU EZGU
Juvenile idiopathic arthritis (JIA) presents with diverse phenotypes and can lead to significant morbidity. Obesity, affecting 5 to 23% of JIA patients, may exacerbate disease activity and complicate management. This study evaluates the impact of body mass index (BMI) on disease activity and the influence of joint involvement on BMI in JIA patients. Between January 2012 and June 2024, 225 JIA patients were reviewed, with 173 ultimately included based on specific inclusion and exclusion criteria. Treatments followed the American College of Rheumatology (ACR) recommendations. Data on demographics, BMI, JADAS-27 scores, joint involvement, and laboratory parameters were analyzed, with statistical significance defined as p < 0.05. Among 173 JIA patients, significant increases in weight and height SDS were observed (p < 0.05). Obese patients at baseline had higher JADAS-27 scores at 6 months (p < 0.05). A positive correlation was found between initial JADAS-27 and final BMI SDS (r = 0.170, p < 0.05). Patients with hip involvement had lower BMI at diagnosis and at the first-year follow-up (p < 0.0001, p = 0.049), while knee involvement was linked to lower height SDS at the second year (p = 0.041). Conclusion: Our study revealed that baseline obesity is a significant risk factor for poorer disease control at the 6-month follow-up in JIA patients. We also observed that effective treatment led to improvements in growth, particularly in patients with hip involvement, who initially had lower BMI values. These findings underscore the importance of monitoring BMI in JIA patients to optimize disease management and long-term outcomes. What is Known:• Overweight and obesity are prevalent in children with JIA, with reported rates ranging from 5 to 23% in various studies.• The relationship between BMI and disease activity in JIA remains controversial, with previous studies reporting conflicting results on whether BMI impacts disease remission or activity. What is New:• Baseline obesity in juvenile idiopathic arthritis (JIA) patients is associated with worse disease activity during follow-up, particularly evident at the 6-month visit.• Patients with hip involvement had significantly lower BMI values, indicating a potential correlation with more severe disease.• Improved linear growth was observed in JIA patients during follow-up, indicating that effective treatment positively impacts growth despite the chronic nature of the disease.

27 January 2026 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
NKNihal Karaçayır
Nihal Karaçayır
MYMerve Yazol
Merve Yazol
EYEmine Nur Sunar Yayla
Emine Nur Sunar Yayla
PŞPelin Esmeray Şenol
Pelin Esmeray Şenol
ÇYÇisem Yıldız
Çisem Yıldız
SBSevcan A. Bakkaloğlu
Sevcan A. Bakkaloğlu
Behçet’s disease (BD) is a chronic inflammatory disorder characterized by recurrent oral aphthous ulcers, genital ulcers, skin lesions, and uveitis. Recent genetic studies have identified monogenic diseases with phenotypes resembling BD, including RELA - associated inflammatory disease (RAID), Haploinsufficiency of A20 (HA20), and otulipenia. The RelA gene encodes the RELA protein, which is involved in the nuclear factor kappa B (NF-κB) signaling pathway that regulates the transcription of genes associated with cell survival, apoptosis, and immune responses. In RAID, dysfunction of the NF-κB pathway leads to reduced cell survival and symptoms of BD, such as recurrent fever, chronic mucocutaneous ulceration, arthralgia, and colitis. Herein, we report a pediatric patient who presented with recurrent, severe oral and genital ulcers from the age of five years and was diagnosed with RAID following a documented RelA gene mutation. The patient responded to a combination of corticosteroids, colchicine and methotrexate. RAID should be considered in the differential diagnosis of patients with early onset recurrent fever and mucosal ulcerations.